Bharat Biotech, an Indian pharmaceutical company, claimed that Covaxin was demonstrated to have 77.8% efficacy against COVID19 patients in the final analysis of the vaccine’s phase 3 clinical trials, APA reports citing Sputnik.
Bharat Biotech added that Covaxin also demonstrated 93.4% effectiveness against severe symptomatic Covid-19 cases.